Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 600.00 | 8.10K | 65.60K | 65.60K | 115.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 600.00 | 8.10K | 65.60K | 65.60K | 115.30K |
| Cost of Revenue | 50.00K | 184.40K | 184.90K | 184.90K | 134.90K |
| Gross Profit | -49.40K | -176.30K | -119.20K | -119.20K | -19.50K |
| SG&A Expenses | 5.08M | 4.82M | 4.75M | 5.36M | 6.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.22M | 10.45M | 11.00M | 11.51M | 11.96M |
| Operating Income | -10.22M | -10.44M | -10.94M | -11.45M | -11.84M |
| Income Before Tax | -8.61M | -12.06M | -13.67M | -15.18M | -15.35M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -8.61 | -12.06 | -13.67 | -15.18 | -15.35 |
| Earnings from Discontinued Operations | 7.43M | 7.43M | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -1.18M | -4.63M | -13.67M | -15.18M | -15.35M |
| EBIT | -10.22M | -10.44M | -10.94M | -11.45M | -11.84M |
| EBITDA | -10.12M | -10.34M | -10.84M | -11.35M | -11.75M |
| EPS Basic | -0.05 | -0.28 | -0.50 | -0.56 | -0.57 |
| Normalized Basic EPS | -0.13 | -0.17 | -0.19 | -0.23 | -0.25 |
| EPS Diluted | -0.05 | -0.28 | -0.50 | -0.56 | -0.57 |
| Normalized Diluted EPS | -0.13 | -0.17 | -0.19 | -0.23 | -0.25 |
| Average Basic Shares Outstanding | 212.64M | 144.01M | 126.03M | 123.59M | 121.37M |
| Average Diluted Shares Outstanding | 212.64M | 144.01M | 126.03M | 123.59M | 121.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
